BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

The BV500 program arose from a successful collaboration within the SmartLab public private partnership with the University of Lille (France) as an incubator for early-stage idea generation, ...

BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against non ...

Bioversys AG has announced that its BV500 NTM program has reached its second milestone with the identification of up to five optimized lead compounds, under the CF AMR Syndicate collaborative ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

BioVersys AG / Key word(s): MiscellaneousBIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CESTBasel, Switzerland. February 11, 2025 ...

The BV500 NTM program is derived from the company’s proprietary Ansamycin Chemistry platform. BioVersys’ research teams in Lille (France) and Basel (Switzerland) have identified and developed several ...